Hepatocellular CarcinomaNCT07368049
MR 7700 Multinuclear Application Clinical Study
A study testing MR Scanning with Phosphorus nucleus + Sodium nucleus in people with Hepatocellular Carcinoma and MRI, run by Philips Clinical & Medical Affairs Global.
Trial summary
The purpose of this clinical study is to perform phosphorus nucleus (31P) and sodium nucleus (23Na) imaging of the liver in patients with primary hepatocellular carcinoma (HCC) and healthy volunteers using the MR 7700 Magnetic Resonance Equipment, in order to explore the manifestations of multinuclear imaging in HCC… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Hepatocellular Carcinoma, MRI
- What is being tested?
- MR Scanning with Phosphorus nucleus + Sodium nucleus
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 5 Jan 2026to 31 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- 1. HCC patient group
- Age ≥ 18 years;
- With clear consciousness, ability to cooperate, and autonomous behavior;
- Voluntary agreement to participate in this clinical trial and signing of the subject's informed consent form;
- Patients diagnosed with primary hepatocellular carcinoma by imaging or clinical diagnosis, and who have not received tumor treatment.
- 2. Healthy control group
Show all 10Show fewer
- Age ≥ 18 years;
- With clear consciousness, ability to cooperate, and autonomous behavior;
- Voluntary agreement to participate in this clinical trial and signing of the subject's informed consent form;
- No previous history of liver disease.
Who cannot join
- HCC patient group and healthy control group
- Patients with claustrophobia.
- Subject's body temperature > 39.5°C on the day of scanning.
- Females who plan to be pregnant within 6 months, and pregnant and lactating females.
- Patients with other implants, prostheses, foreign bodies, patches, etc. that are not suitable for MRI examination; patients with electronic implants, such as pacemakers, stimulators, insulin pumps, cochlear implants, etc.
- Critically ill subjects with various resuscitation devices or those with any emergency medical condition requiring first aid.
- Subjects with poor compliance are considered to be excluded by the investigators.
- Subjects who are not considered suitable for this trial by the investigators.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The purpose of this clinical study is to perform phosphorus nucleus (31P) and sodium nucleus (23Na) imaging of the liver in patients with primary hepatocellular carcinoma (HCC) and healthy volunteers using the MR 7700 Magnetic Resonance Equipment, in order to explore the manifestations of multinuclear imaging in HCC patients and healthy volunteers.
- Conditions
- Hepatocellular Carcinoma, MRI
- Being tested
- MR Scanning with Phosphorus nucleus + Sodium nucleus
- Keywords
- HCC, multinuclear, MR, Liver
- Medical subject headings
- Carcinoma, Hepatocellular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MR Scanning with Phosphorus nucleus + Sodium nucleusDevice
Using the Magnetic Resonance Equipment to perform phosphorus nucleus (31P) and sodium nucleus (23Na) scanning
| Study group | Role | What they receive |
|---|---|---|
| HCC patients | Experimental | HCC patients Receives: Device: MR Scanning with Phosphorus nucleus + Sodium nucleus |
| Healthy volunteers | Placebo comparator | Healthy volunteers Receives: Device: MR Scanning with Phosphorus nucleus + Sodium nucleus |
What is being measured
The primary outcome is the main question the study is designed to answer.
Ratio of metabolites （PME/PDE）
By comparing the ratios of metabolites (PME/PDE) in the liver, the effectiveness of 31P magnetic resonance spectroscopy (31P-MRS) was evaluated.
Theoretically,the PME/PDE ratio in patients with HCC was higher than that in healthy volunteers.
Measured: 14 days (anticipated)] after finishing 31P-MRS scanning
Image quality of 23Na-MRI
Image quality will be assessed by Likert score (1-5)
Measured: 14 days (anticipated)] after finishing 23Na-MRI scanning
Adverse Event
Monitor adverse events and serious adverse events during the study,summarize and analyze the frequency and percentage of all adverse events (including severe adverse events)
Measured: From the time the subjects signed the ICF to completion of study visit(1 day).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2026
- Study start5 Jan 2026 (estimated)
- Primary completion30 Jun 2026 (estimated)
- Study completion31 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatocellular CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Philips Clinical & Medical Affairs Global
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07368049
- Sponsor's protocol ID
- 301455
- Status last verified
- Jan 2026
- First submitted
- 24 Nov 2025
- Last updated
- 26 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MR 7700 Multinuclear Application Clinical Study
- ClinicalTrials.gov ID
- NCT07368049
- Acronym / sponsor ID
- 301455
- Conditions
- Hepatocellular Carcinoma, MRI
- Keywords
- HCC, multinuclear, MR, Liver
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Philips Clinical & Medical Affairs GlobalIndustry (pharma, biotech, devices)
- Study start
- 5 Jan 2026 (estimated)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 31 Aug 2026 (estimated)
- First posted
- 26 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this clinical study is to perform phosphorus nucleus (31P) and sodium nucleus (23Na) imaging of the liver in patients with primary hepatocellular carcinoma (HCC) and healthy volunteers using the MR 7700 Magnetic Resonance Equipment, in order to explore the manifestations of multinuclear imaging in HCC patients and healthy volunteers.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| HCC patients | Experimental | Device: MR Scanning with Phosphorus nucleus + Sodium nucleusHCC patients |
| Healthy volunteers | Placebo comparator | Device: MR Scanning with Phosphorus nucleus + Sodium nucleusHealthy volunteers |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- 1. HCC patient group
- 2. Healthy control group
Key exclusion criteria (8 listed)
- HCC patient group and healthy control group
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MR Scanning with Phosphorus nucleus + Sodium nucleusUsing the Magnetic Resonance Equipment to perform phosphorus nucleus (31P) and sodium nucleus (23Na) scanning | Device | HCC patients, Healthy volunteers |
Primary outcome
Ratio of metabolites （PME/PDE）
Time frame: 14 days (anticipated)] after finishing 31P-MRS scanning
By comparing the ratios of metabolites (PME/PDE) in the liver, the effectiveness of 31P magnetic resonance spectroscopy (31P-MRS) was evaluated. Theoretically,the PME/PDE ratio in patients with HCC was higher than that in healthy volunteers.
Image quality of 23Na-MRI
Time frame: 14 days (anticipated)] after finishing 23Na-MRI scanning
Image quality will be assessed by Likert score (1-5)
Adverse Event
Time frame: From the time the subjects signed the ICF to completion of study visit(1 day).
Monitor adverse events and serious adverse events during the study,summarize and analyze the frequency and percentage of all adverse events (including severe adverse events)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Hepatocellular Carcinoma
Not yet recruitingPhase 3
Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Not yet recruiting
Overcoming Immunotherapy Resistance in Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-Resectable
RecruitingPhase 2
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma, HCC
Active, not recruitingPhase 2
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma
RecruitingPhase 1/2
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Recurrent or Metastatic Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing MR Scanning with Phosphorus nucleus + Sodium nucleus in people with Hepatocellular Carcinoma and MRI, run by Philips Clinical & Medical Affairs Global.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Fu Hua Yan ((+86)13661850380, yfh11655@rjh.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ratio of metabolites （PME/PDE） (time frame: 14 days (anticipated)] after finishing 31P-MRS scanning). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.